Filing Flows › Tenet Healthcare (THC) › Guidance & outlook
Tenet Healthcare (THC) guidance and outlook
Tenet Healthcare (THC) raised its guidance on Oct 29, 2026: EBITDA $5.0B–$5.2B for FY2026; Free cash flow $2.8B–$3.1B for FY2026; EBITDA margin 22.9%–23.2% for FY2026; EPS $35.82–$37.08 for FY2026. Tenet Healthcare's 10-Q filed Oct 29, 2026 makes 5 forward-looking statements, 2 of them new and 5 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EBITDA | FY2026 | $5.0B–$5.2B | raised |
| Free cash flow | FY2026 | $2.8B–$3.1B | raised |
| EBITDA margin | FY2026 | 22.9%–23.2% | raised |
| EPS | FY2026 | $35.82–$37.08 | raised |
| EPS | FY2026 | $22.05–$23.01 | raised |
| Revenue | FY2026 | +3% to +6% | new |
| Tax rate | FY2026 | 21% | reaffirmed |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 29, 2026
- new · During the three months ended September 30, 2026, we assessed the periods over which we expect to satisfy the performance obligations under the CHI Agreements based on our current transition progress.
- new · We will substantially complete the transition by October 30, 2026 rather than December 31, 2026, as originally expected.
- We anticipate that our capital expenditures for the year ending December 31, 2026 will total approximately $700 million to $800 million, including $111 million that was accrued as a liability at December 31, 2025.
- We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities are adequate to meet our current cash needs.
- From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and the financing alternatives available at that time.
Tenet Healthcare's latest quarter
Tenet Healthcare, Q3 2026: revenue $5.6B (+6% year over year), operating margin 31.1%, net earnings $1.0B, operating cash flow $1.3B. The chart follows the revenue to costs, profit and cash.
Questions
Did Tenet Healthcare raise or lower its guidance?
Tenet Healthcare (THC) raised its guidance on Oct 29, 2026: EBITDA $5.0B–$5.2B for FY2026; Free cash flow $2.8B–$3.1B for FY2026; EBITDA margin 22.9%–23.2% for FY2026; EPS $35.82–$37.08 for FY2026.
What does Tenet Healthcare expect?
During the three months ended September 30, 2026, we assessed the periods over which we expect to satisfy the performance obligations under the CHI Agreements based on our current transition progress. We will substantially complete the transition by October 30, 2026 rather than December 31, 2026, as originally expected.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.